Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is focused on building a “best-in-class” genome editing platform and rapidly moving curative therapies towards the clinic.
Our company’s unique strengths include the expertise of our team in discovering and developing genome editing products, our proprietary versatile lipid nanoparticle delivery system, and our focus on both in vivo and ex vivo product development.
Intellia brings its impressive capabilities, plus all the virtues of good partnering to all our collaborations: Vision, integrity, expertise, reliability and teamwork.
We are proud to count revolutionizing biopharmaceutical companies and leading academic institutions as partners – organizations that share our determination to revolutionize medical science. Our scientific progress is rapid, and there are many opportunities to share in this progress.
We seek strategic collaborators to unlock the full potential of CRISPR/Cas9 genome editing. We scout for cutting-edge technologies that advance the application of CRISPR/Cas9 for human therapeutics and our genome editing platforms, including:
- Genome modifying technologies
- Recombination and DNA repair technologies
- RNA therapeutic technologies
- Therapeutic delivery of nucleic acids or ribonucleoproteins – viral and chemical
- Engineered immune cell technologies
- Novel target identification
If you are interested in exploring genome editing science and its translation into human therapies, or if your technology could advance the science, please contact us.
- In December 2014, Intellia entered into a strategic collaboration and license agreement with Novartis, focusing on accelerating the development of new ex vivo CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CAR-Ts) and hematopoietic stem cells (HSCs). View Press Release
- In December 2018, Intellia and Novartis expanded their cell therapy collaboration to research ex vivo CRISPR/Cas9-based cell therapies using certain ocular stem cells. View Press Release
- The collaboration portion of the agreement ended in December 2019, with each party continuing to advance selected programs after the collaboration term.
- Under the original collaboration agreement, Novartis and Intellia worked to discover HSC targets, and both continue to develop their own proprietary internal HSC pipeline. Novartis received exclusive rights to develop all collaboration programs focused on engineered CAR-Ts during the collaboration term, and is now advancing a limited number of selected CAR-T programs. Intellia is eligible to receive downstream success-based milestones and royalties on these programs.
- Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
- In April 2016, Intellia entered into a license and collaboration agreement with Regeneron. The agreement includes a product component under which the companies will research, develop and commercialize CRISPR/Cas-based therapeutic products primarily focused on genome editing in the liver. There is also a technology collaboration component in which Intellia and Regeneron will perform research and development activities aimed at discovering and developing novel technologies and improvements to CRISPR/Cas technology to enhance our therapeutic genome editing platform. View Press Release
- Under the terms of the agreement, Regeneron has the exclusive right to discover and develop CRISPR-based products against up to 10 target genes, focused primarily on therapies for a broad range of diseases that may be treated by editing genes in the liver. Transthyretin amyloidosis (ATTR) is the first indication for which products will be jointly developed and potentially commercialized by the companies.
- Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and over a dozen product candidates in development. Regeneron’s medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, and infectious and rare diseases. Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies and ambitious initiatives such as The Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
- In July 2014, Intellia entered into license and service agreements with Caribou Biosciences. Caribou granted Intellia an exclusive license to its CRISPR/Cas9 intellectual property for human therapeutic use excluding anti-fungal and anti-microbial applications. View Press Release
- Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of creating new medical therapies. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited cell therapies and engineered gut microbes. For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio.
- In June 2017, Intellia entered into a three-year research collaboration, option and license agreement with Ospedale San Raffaele (“OSR”) to engineer optimized T cell-based cancer therapies.
- The collaboration has resulted in Intellia’s first ex vivo development candidate, which is a T cell therapy for acute myeloid leukemia (AML) targeting the Wilms’ Tumor protein (WT1). In December 2019, Intellia exercised its option to obtain an exclusive license to OSR’s intellectual property developed under the collaboration, including patent applications directed to WT1-specific T cell receptors.
- OSR is a leading European research-university hospital near Milan, Italy. Scientific research at OSR covers virtually all fields of biomedical research. OSR seeks to integrate basic, translational and clinical research to provide the best assistance to patients. For further information, visit: hsr.it.